Telemetry Investments’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Telemetry Investments’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50,000	Closed	-$10K	–	185
2018 Q1	$10K	Sell	50,000 -14,464	-22%	-$13.3K	﹤0.01%	140
2017 Q4	$83K	Buy	+64,464	New	+$105K	0.03%	128
2017 Q3	–	Sell	-70,253	Closed	-$204K	–	169
2017 Q2	$204K	Sell	70,253 -18,016	-20%	-$54K	0.1%	103
2017 Q1	$304K	Buy	88,269 +78,019	+761%	+$308K	0.14%	83
2016 Q4	$18K	Hold	10,250	–	–	0.01%	103
2016 Q3	$34K	Hold	10,250	–	–	0.02%	110
2016 Q2	$44K	Hold	10,250	–	–	0.02%	115
2016 Q1	$58K	Sell	10,250 -450	-4%	-$5.84K	0.02%	97
2015 Q4	$184K	Hold	10,700	–	–	0.06%	111
2015 Q3	$226K	Buy	10,700 +3,696	+53%	+$127K	0.1%	103
2015 Q2	$347K	Sell	7,004 -39,300	-85%	-$2.35M	0.16%	109
2015 Q1	$3.63M	Buy	46,304 +16,994	+58%	+$1.05M	2%	14
2014 Q4	$1.78M	Buy	+29,310	New	+$1.47M	1.1%	21

Other funds holding OREX

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Telemetry Investments's OREX Position: Q2 2018 in Review

Telemetry Investments sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 50,000 shares — an estimated $10K sold.

Telemetry Investments first reported a position in OREX in Q4 2014 and held it in 13 quarters. The position peaked at $3.63M in Q1 2015. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

Telemetry Investments reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Telemetry Investments sold 50,000 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $10K.
Telemetry Investments first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
Telemetry Investments's Orexigen Therapeutics, Inc. position peaked at $3.63M in Q1 2015.
4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on Telemetry Investments's 13F filing for Q2 2018, filed 14 Aug 2018.